Free Trial
NASDAQ:ACON

Aclarion Q3 2025 Earnings Report

Aclarion logo
$3.57 +0.04 (+1.13%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$3.42 -0.16 (-4.34%)
As of 06/5/2026 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclarion EPS Results

Actual EPS
-$2.93
Consensus EPS
-$2.64
Beat/Miss
Missed by -$0.29
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.02 million
Beat/Miss
Missed by -$1.06 thousand
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Aclarion's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Aclarion Earnings Headlines

Wall Street Zen Downgrades Aclarion (NASDAQ:ACON) to Sell
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

View Aclarion Profile